Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.
about
Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytesPPARs in the Renal Regulation of Systemic Blood PressureRosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse heartsSuccessful drug development despite adverse preclinical findings part 2: examples.Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl.Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs.Peroxisome Proliferator-Activated Receptor γ Activity is Required for Appropriate Cardiomyocyte DifferentiationPPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?Serum Natriuretic Peptides as Differential Biomarkers Allowing for the Distinction between Physiologic and Pathologic Left Ventricular Hypertrophy.PPARgamma Agonists: Blood Pressure and Edema.Metformin prevents the development of chronic heart failure in the SHHF rat model.Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression.Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischaemia-reperfusion.Fluid Retention Caused by Rosiglitazone Is Related to Increases in AQP2 and αENaC Membrane Expression.Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart.
P2860
Q28579542-A6104BA9-D67D-4DA3-B295-DC2B652A0F6DQ33960908-E0BD164A-D885-4C5A-8293-2A069A83CA77Q34569388-D030708B-53E4-4CF9-A9DB-D7454CBEE1F5Q35603965-FF38FEE0-D94D-4FB4-BD66-E00C28DFCD75Q36083217-96C3EF5E-4B5A-48FE-A5EF-EE86A59DF46AQ36261098-4E58E888-4A38-4D57-9067-0102E611BFA3Q37183230-F8DB6A8C-3F26-41A0-BFE2-5F45DAB84676Q39740098-72B88770-B6E3-48F8-887D-5854BD3084EEQ39832237-B0F7567A-2E91-46ED-967B-141F2105596AQ41876733-0709A22E-1434-436D-B940-8EED7FFA3E80Q41885618-2920F22F-391E-4EA0-8483-F126565C05B4Q42719651-C4AD75CF-948F-4086-9043-9C940DDADD52Q44797718-4AF76095-CEF9-429D-A051-452E4541FA79Q47104757-72DA754F-8F45-436F-B37F-7B2A5FB4BC11Q47372080-84AE429F-427B-487B-82D6-1C1E32D49AFC
P2860
Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@en
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@nl
type
label
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@en
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@nl
prefLabel
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@en
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@nl
P2093
P2860
P356
P1433
P1476
Effects of chronic PPAR-agonis ...... n healthy sprague-dawley rats.
@en
P2093
Aileen McHarg
Carolyn M Ecelbarger
Eileen R Blasi
Jonathan Heyen
Michelle Hemkens
Swasti Tiwari
P2860
P304
P356
10.1155/2009/237865
P577
2009-06-11T00:00:00Z